<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Canton Strategic Holdings, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/canton-strategic-holdings-inc</link>
    <description>Latest news and press releases for Canton Strategic Holdings, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 13:15:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/canton-strategic-holdings-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7442451cc36e475331fed.webp</url>
      <title>Canton Strategic Holdings, Inc.</title>
      <link>https://6ix.com/company/canton-strategic-holdings-inc</link>
    </image>
    <item>
      <title>Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update</title>
      <link>https://6ix.com/company/canton-strategic-holdings-inc/news/canton-strategic-holdings-inc-presents-quarterly-canton-network-ecosystem-update</link>
      <guid isPermaLink="true">https://6ix.com/company/canton-strategic-holdings-inc/news/canton-strategic-holdings-inc-presents-quarterly-canton-network-ecosystem-update</guid>
      <pubDate>Mon, 20 Apr 2026 13:15:00 GMT</pubDate>
      <description>Canton Strategic Holdings, Inc., (NASDAQ: CNTN) (&quot;Canton Strategic Holdings&quot; or the &quot;Company&quot;) the first publicly traded company to leverage Canton Coin to support the Canton Network&apos;s ability to digitize traditional financial markets, today announced the launch of its quarterly ecosystem update on the Canton Network for the first quarter of 2026, a comprehensive analysis of network activity to be followed by a live webinar on April 22, 2026.</description>
    </item>
    <item>
      <title>Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board</title>
      <link>https://6ix.com/company/canton-strategic-holdings-inc/news/canton-strategic-holdings-inc-chairman-and-ceo-mark-wendland-elected-to-canton-foundation-board</link>
      <guid isPermaLink="true">https://6ix.com/company/canton-strategic-holdings-inc/news/canton-strategic-holdings-inc-chairman-and-ceo-mark-wendland-elected-to-canton-foundation-board</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>Appointment Underscores Canton Strategic Holdings&apos; Leadership Role in Accelerating Institutional Adoption of the Canton NetworkNEW YORK, March 3, 2026</description>
    </item>
    <item>
      <title>Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors</title>
      <link>https://6ix.com/company/canton-strategic-holdings-inc/news/tharimmune-announces-key-leadership-appointments-including-james-gordon-liddy-joining-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/canton-strategic-holdings-inc/news/tharimmune-announces-key-leadership-appointments-including-james-gordon-liddy-joining-board-of-directors</guid>
      <pubDate>Tue, 17 Jun 2025 04:00:00 GMT</pubDate>
      <description>BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of</description>
    </item>
    <item>
      <title>Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)</title>
      <link>https://6ix.com/company/canton-strategic-holdings-inc/news/tharimmune-announces-option-agreement-for-key-technologies-for-generating-her2her3-antibody-drug-conjugates-adcs</link>
      <guid isPermaLink="true">https://6ix.com/company/canton-strategic-holdings-inc/news/tharimmune-announces-option-agreement-for-key-technologies-for-generating-her2her3-antibody-drug-conjugates-adcs</guid>
      <pubDate>Tue, 23 Apr 2024 04:00:00 GMT</pubDate>
      <description>Obtained rights from Washington University to develop and incorporate human HER2 directed antibodiesComplements early pipeline of novel tunable &quot;Knob domain&quot;</description>
    </item>
  </channel>
</rss>